These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10851487)

  • 1. Modeling of internal dose distributions during SR-89 treatment of a patient with bone metastases.
    Bialkowski MM; Wierzbicki JG; Porter AT
    Cancer Biother Radiopharm; 1997 Oct; 12(5):355-62. PubMed ID: 10851487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases.
    Li WB; Höllriegl V; Roth P; Oeh U
    Radiat Environ Biophys; 2008 Apr; 47(2):225-39. PubMed ID: 18204850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Strontium-89 for bone metastases from prostate cancer: an update].
    Zhao WW; Xie P; Deng HF
    Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma.
    Blake GM; Zivanovic MA; McEwan AJ; Condon BR; Ackery DM
    Br J Radiol; 1987 Mar; 60(711):253-9. PubMed ID: 3471288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
    Laing AH; Ackery DM; Bayly RJ; Buchanan RB; Lewington VJ; McEwan AJ; Macleod PM; Zivanovic MA
    Br J Radiol; 1991 Sep; 64(765):816-22. PubMed ID: 1717094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
    Ouyang W; Liu JH; Liu WY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):390-1. PubMed ID: 17426002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.
    Blake GM; Zivanovic MA; Blaquiere RM; Fine DR; McEwan AJ; Ackery DM
    J Nucl Med; 1988 Apr; 29(4):549-57. PubMed ID: 3351609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radionuclide-targeted therapy for the management of metastatic bone pain.
    Ackery D; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palliation of multiple bone metastases from prostatic carcinoma with strontium-89.
    Tennvall J; Darte L; Lundgren R; el Hassan AM
    Acta Oncol; 1988; 27(4):365-9. PubMed ID: 2462438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
    Kan MK
    Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of strontium-89 palliative therapy in patients with painful bone metastases.
    Zorga P; Birkenfeld B; Listewnik MH; Piwowarska-Bilska H
    Ann Acad Med Stetin; 2011; 57(1):49-53; discussion 53. PubMed ID: 22593991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A direct measurement of strontium-89 activity in bone metastases.
    Ben-Josef E; Maughan RL; Vasan S; Porter AT
    Nucl Med Commun; 1995 Jun; 16(6):452-6. PubMed ID: 7675358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis.
    Blake GM; Gray JM; Zivanovic MA; McEwan AJ; Fleming JS; Ackery DM
    Br J Radiol; 1987 Jul; 60(715):685-92. PubMed ID: 3620827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possibilities of systemic radiotherapy with high-purity 89Sr chloride in the treatment of bone metastases].
    Fomin DK; Tararukhina OB; Nazarov AA
    Vestn Rentgenol Radiol; 2012; (2):29-31. PubMed ID: 22730757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma.
    Blake GM; Zivanovic MA; McEwan AJ; Batty VB; Ackery DM
    Eur J Nucl Med; 1987; 13(1):41-6. PubMed ID: 3109917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strontium 89 in the treatment of bony metastases.
    Porter AT; Ben-Josef E
    Important Adv Oncol; 1995; ():87-94. PubMed ID: 7545646
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in the levels of CD4+ and CD8+ T-lymphocytes after strontium-89 chloride therapy for painful bone metastases in patients correlate with treatment efficacy.
    Li Y; Li XF; Ma Y; Fang N; Russell J; Ma D; Sun X; Han X; Yang H; Kinuya S
    Cancer Biother Radiopharm; 2007 Jun; 22(3):367-73. PubMed ID: 17651042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of symptomatic bone metastases of prostatic carcinoma using strontium chloride (Sr-89)].
    Dormia E; Mantovani F; Minervini S; Malagola G; Castellani R; Dormia G; Gonnella G; Mazza L; Luongo P; Bertana F
    Arch Ital Urol Androl; 1993 Apr; 65(2):161-6. PubMed ID: 8330061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.